Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

unknown150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_2

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

NCT02416388
unknownphase_2

Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

NCT04216771

Clinical Trials (2)

Showing 2 of 2 trials
NCT02416388Phase 2

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
NCT04216771Phase 2

Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2